Skip to main content
Erschienen in: Archives of Dermatological Research 2/2012

01.03.2012 | Original Paper

Comparison of the spread of three botulinum toxin type A preparations

verfasst von: Martina Kerscher, Susanna Roll, Andreas Becker, Walter Wigger-Alberti

Erschienen in: Archives of Dermatological Research | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Botulinum toxins are frequently used in esthetics to improve the appearance of facial wrinkles. In this setting, precise localization of the neurotoxin is required to produce the desired clinical effects. Unwanted effects can occur if the neurotoxin diffuses into untargeted muscle. Therefore, a neurotoxin with low and predictable spread would be preferable for esthetic applications. The aim of this study was to investigate the spread of three approved botulinum toxin type A preparations, with and without complexing proteins, by measuring and comparing the size of the anhidrotic halos they produced following injection of equivalent doses in an identical volume into the forehead of patients. The results showed that incobotulinumtoxinA and onabotulinumtoxinA displayed comparable spread at 6 weeks (maximal area of anhidrosis within 6 weeks) and area under the effect curve (AUEC) over 6 months. However, abobotulinumtoxinA, when assuming a 1:2.5 injection volume ratio, produced a statistically significantly greater maximal area of anhidrosis within 6 weeks and AUEC over 6 months compared with incobotulinumtoxinA. All preparations were well tolerated. The results of this study demonstrate that incobotulinumtoxinA and onabotulinumtoxinA have comparable spread, while abobotulinumtoxinA has significantly greater spread than incobotulinumtoxinA.
Literatur
1.
Zurück zum Zitat Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J (2004) A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51:223–233PubMedCrossRef Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J (2004) A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51:223–233PubMedCrossRef
2.
Zurück zum Zitat Ascher B, Rzany BJ, Grover R (2009) Efficacy and safety of botulinum toxin type A in the treatment of lateral crow’s feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 35:1478–1486PubMedCrossRef Ascher B, Rzany BJ, Grover R (2009) Efficacy and safety of botulinum toxin type A in the treatment of lateral crow’s feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 35:1478–1486PubMedCrossRef
3.
Zurück zum Zitat Benecke R, Jost W, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951PubMedCrossRef Benecke R, Jost W, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951PubMedCrossRef
4.
Zurück zum Zitat Carruthers A, Kiene K, Carruthers J (1996) Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol 34:788–797PubMedCrossRef Carruthers A, Kiene K, Carruthers J (1996) Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol 34:788–797PubMedCrossRef
5.
Zurück zum Zitat Carruthers A, Carruthers J (2008) Botulinum toxin products overview. Skin Ther Lett 13:1–5 Carruthers A, Carruthers J (2008) Botulinum toxin products overview. Skin Ther Lett 13:1–5
6.
Zurück zum Zitat Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N (2002) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46:840–849PubMedCrossRef Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N (2002) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46:840–849PubMedCrossRef
7.
Zurück zum Zitat Cliff SH, Judodihardjo H, Eltringham E (2008) Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol 7:50–54PubMedCrossRef Cliff SH, Judodihardjo H, Eltringham E (2008) Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol 7:50–54PubMedCrossRef
8.
Zurück zum Zitat de Almeida AT, De Boulle KJ (2007) Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 9(Suppl 1):17–22PubMedCrossRef de Almeida AT, De Boulle KJ (2007) Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 9(Suppl 1):17–22PubMedCrossRef
9.
Zurück zum Zitat De Boulle K, Fragien S, Sommer B, Glogau R (2010) Treating glabellar lines with botulinum toxin type-A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction. Clin Interv Aging 5:101–118PubMedCrossRef De Boulle K, Fragien S, Sommer B, Glogau R (2010) Treating glabellar lines with botulinum toxin type-A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction. Clin Interv Aging 5:101–118PubMedCrossRef
10.
Zurück zum Zitat De Maio M, Rzany B (2007) Botulinum toxin in aesthetic medicine. Springer, Heidelberg, GermanyCrossRef De Maio M, Rzany B (2007) Botulinum toxin in aesthetic medicine. Springer, Heidelberg, GermanyCrossRef
11.
Zurück zum Zitat Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29:1761–1768PubMedCrossRef Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29:1761–1768PubMedCrossRef
12.
Zurück zum Zitat Eisele KH, Fink K, Vey M, Taylor HV (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57:555–565PubMedCrossRef Eisele KH, Fink K, Vey M, Taylor HV (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57:555–565PubMedCrossRef
13.
Zurück zum Zitat Hexsel D, Dal’Forno T, Hexsel C, Do Prado DZ, Lima MM (2008) A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Sur 34:52–59CrossRef Hexsel D, Dal’Forno T, Hexsel C, Do Prado DZ, Lima MM (2008) A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Sur 34:52–59CrossRef
14.
Zurück zum Zitat Hsu TS, Dover JS, Arndt KA (2004) Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 140:1351–1354PubMedCrossRef Hsu TS, Dover JS, Arndt KA (2004) Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 140:1351–1354PubMedCrossRef
15.
Zurück zum Zitat Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K, Oguma K (1996) Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 64:1589–1594PubMed Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K, Oguma K (1996) Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 64:1589–1594PubMed
16.
Zurück zum Zitat Jost WH, Kohl A, Brinkmann S, Comes G (2005) Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (Botox®) in healthy volunteers. J Neural Transm 112:905–913PubMedCrossRef Jost WH, Kohl A, Brinkmann S, Comes G (2005) Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (Botox®) in healthy volunteers. J Neural Transm 112:905–913PubMedCrossRef
17.
Zurück zum Zitat Kanovský P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, Grafe S (2009) Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 32:259–265PubMedCrossRef Kanovský P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, Grafe S (2009) Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 32:259–265PubMedCrossRef
18.
Zurück zum Zitat Karsai S, Raulin C (2009) Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 35:1–8PubMedCrossRef Karsai S, Raulin C (2009) Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 35:1–8PubMedCrossRef
19.
Zurück zum Zitat Klein A, Carruthers A, Fagien S, Lowe NJ (2008) Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg 121:413e–422ePubMedCrossRef Klein A, Carruthers A, Fagien S, Lowe NJ (2008) Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg 121:413e–422ePubMedCrossRef
20.
Zurück zum Zitat Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N (2005) Double-blind, randomised, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet. Dermatol Surg 31:257–262PubMedCrossRef Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N (2005) Double-blind, randomised, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet. Dermatol Surg 31:257–262PubMedCrossRef
21.
Zurück zum Zitat Minor V (1928) Ein neues verfahren zu der klinischen untersuchung der schweiβabsonderung. Deutsch Z Nervenhlk 101:302–308CrossRef Minor V (1928) Ein neues verfahren zu der klinischen untersuchung der schweiβabsonderung. Deutsch Z Nervenhlk 101:302–308CrossRef
22.
Zurück zum Zitat Monheit G, Carruthers A, Brandt F, Rand R (2007) A randomised, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 33:S51–S59PubMedCrossRef Monheit G, Carruthers A, Brandt F, Rand R (2007) A randomised, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 33:S51–S59PubMedCrossRef
23.
Zurück zum Zitat Roggenkämper P, Jost W, Bihari K, Comes G, Grafe S (2006) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303–312PubMedCrossRef Roggenkämper P, Jost W, Bihari K, Comes G, Grafe S (2006) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303–312PubMedCrossRef
24.
Zurück zum Zitat Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R (2007) Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 33:S37–S43PubMedCrossRef Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R (2007) Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 33:S37–S43PubMedCrossRef
25.
Zurück zum Zitat Wohlfarth K, Muller C, Sassin I, Comes G, Grafe S (2007) Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Clin Neuropharmacol 30:86–94PubMedCrossRef Wohlfarth K, Muller C, Sassin I, Comes G, Grafe S (2007) Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Clin Neuropharmacol 30:86–94PubMedCrossRef
Metadaten
Titel
Comparison of the spread of three botulinum toxin type A preparations
verfasst von
Martina Kerscher
Susanna Roll
Andreas Becker
Walter Wigger-Alberti
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Archives of Dermatological Research / Ausgabe 2/2012
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-011-1179-z

Weitere Artikel der Ausgabe 2/2012

Archives of Dermatological Research 2/2012 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.